January 30, 2013
The first human study of the cell proliferation marker F18-ISO-1 indicated its safety and feasibility and suggested it may be used to stratify patients into high and low Ki-67 proliferative groups. The study was published online Jan. 28 in The Journal of Nuclear Medicine .
Measurements of cell proliferation can be used to predict and determine response to therapy and may inform the development of new agents. F18-FLT, a PET proliferation marker, underestimates the proliferative status of solid tumors. Ki-67 provides a marker for all phases of the cell cycle, but it requires a biopsy specimen or surgical resection, which is not possible for all tumors. Consequently, there is a need for a noninvasive means to measure the proliferative status of solid tumors.